Paul Volkert, MD
Cardiovascular Disease · Janesville, WINPI 1437143435
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Amgen at 58.1% of the total. Reporting peaked in 2019 at $11,164 and has fallen 99.0% since, to $116 in 2025. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $86.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- Medtronic$3K
- Boston Scientific$2K
- Cardiovascular Systems Inc.$593
- Veryan Medical Incorporated$337
- Angiodynamics, Inc.$304
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$9,46854%
- Travel & lodging$3,37119%
- Food & beverage$4,43425%
- Education$2171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $10,159 |
| Medtronic(2 entities) | 52 | $3,312 |
| Boston Scientific | 33 | $1,776 |
| Cardiovascular Systems Inc. | 39 | $593 |
| Veryan Medical Incorporated | 8 | $337 |
| Angiodynamics, Inc. | 8 | $304 |
| AstraZeneca | 8 | $276 |
| Novartis | 12 | $215 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Daiichi Sankyo Inc. | 3 | $79 |
| Kestra Medical Technology Services, Inc. | 1 | $52 |
| Johnson & Johnson | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| Teleflex LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Surmodics, Inc. | 1 | $22 |
| Biosense Webster, Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $22 |
| Abbott | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| BD | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$9,959
- HawkOne$1,270
- Abre$923
- JETSTREAM$876
- Auryon Laser System 100-120 Vac$220
- ELUVIA$139
- Peripheral Orbital Atherectomy System$127
- BioMimics 3D Vascular Stent System$118
- SYNERGY$118
How this compares
$17,490 in reported general payments places this provider in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $155,355 |
| XareltoRivaroxaban | 23 | $20,183 |
| Repatha SureclickEvolocumab | 21 | $19,299 |
| BrilintaTicagrelor | 14 | $14,753 |
| Repatha SyringeEvolocumab | 16 | $9,446 |
| Repatha PushtronexEvolocumab | 13 | $8,965 |
| Metoprolol Succinate | 57 | $1,278 |
| Atorvastatin Calcium | 137 | $1,169 |
| ClopidogrelClopidogrel Bisulfate | 82 | $1,117 |
| Rosuvastatin Calcium | 55 | $1,084 |
| Potassium Chloride | 24 | $706 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $682 |
| Losartan Potassium | 67 | $656 |
| Furosemide | 101 | $643 |
| Metoprolol Tartrate | 114 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $52 | $20,18323 claims |
| AstraZenecaBrilinta | $276 | $14,75314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Janesville
- Imdad AhmedJanesville$164K
- Eugene GulliverJanesville$8K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.